$EVH

Evolent Health (EVH) reported Q2 revenue of $652.5M, up 46.9% YoY, beating estimates. Astrana Health (ASTH) reported $972.5M, up 48.5%, missing estimates. Tandem Diabetes (TNDM) reported $254.6M, up 5.8%, in line with estimates. GoodRx (GDRX) reported $200.4M, down 1.3%, beating estimates. All stocks rose post-earnings.

Evolent Health (EVH) reported Q2 2026 revenue of $652.5M versus $444.3M a year earlier, citing the Highmark contract launch. Net loss attributable to common shareholders was $28.4M. Adjusted EBITDA was $28.1M. Full-year 2026 revenue guidance was raised to $2.6B-$2.7B and adjusted EBITDA to $120M-$135M. 2027 revenue growth is expected to exceed 25%.

Evolent Health (EVH) Q2 results beat Wall Street on revenue and profitability, helped by a successful Highmark contract launch and strong customer renewals, according to management. CEO Seth Blackley said clinical engagement for new partnerships like Aetna and Highmark is above target, and automation via Auth Intelligence improved efficiency. Analysts asked about reserving, margins, oncology costs, Medicaid headwinds, and the pipeline.

Wall Street analysts issued multiple rating changes. Argus upgraded Boeing (BA) to Buy and set a $265 target; Truist upgraded Best Buy (BBY) to Buy with a $95 target; Argus upgraded Centene (CNC) to Buy with an $80 target. Other moves included UBS upgrading Jabil (JBL) to Buy, BofA downgrading AppLovin (APP) to Neutral, and Barclays downgrading Under Armour (UAA) to Underweight.

Evolent Health (EVH) reported Q2 call highlights. Management said its Aetna partnership continued producing clinical engagement above targets, while claims-based results met expectations. For 3Q-4Q, revenue is expected to be meaningfully above Q2 on Performance Suite. Evolent signed an oncology Performance Suite deal expected to add about $300M annualized revenue, and expects 2027 revenue growth over 25% and 2027 adj. EBITDA midpoint at or above $150M.

Evolent Health (EVH) reported Q2 CY2026 revenue of $652.5 million, up 46.9% year on year, beating Wall Street expectations. Full-year revenue guidance of $2.65 billion at the midpoint was 5.9% above analysts’ estimates. Non-GAAP EPS was $0.02. Management cited Highmark contract launch, renewals, and scaling of its Auth Intelligence AI automation, while noting Medicaid and exchange membership headwinds.

Evolent Health (EVH) shares rose 23.4% in pre-market after the company reported Q2 2026 results. According to the article, EPS was $0.02 versus -$0.01 expected, and revenue was $652.52M versus $597.46M expected, up about 47% year over year. The move was linked to short interest with days to cover near 5.67 and multiple EPS estimate revisions.

Evolent Health (NYSE: EVH) reported Q2 2026 results for the three months ended June 30, 2026 and raised 2026 revenue guidance to $2.6 to $2.7 billion and Adjusted EBITDA to $120 to $135 million. The company expects 2027 revenue growth of over 25% and Adjusted EBITDA midpoint at or above $150 million. It also outlined two partnership updates, including a $300 million annualized oncology deal.

Evolent Health, Inc. (EVH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Evolent Announces Second Quarter 2026 Results WASHINGTON (August 6, 2026) – Evolent Health, Inc. (NYSE: EVH) (“Evolent” or the “Company”), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make healt

Evolent Health (EVH) reports earnings Thursday before market hours. Last quarter, it posted revenue of $496.2M, up 2.6% YoY, missing analysts’ revenue expectations, while EPS beat. For the upcoming quarter, analysts expect revenue growth of 34.3% YoY. EVH is down 46.1% over the past month versus an average peer gain, with an analyst price target of $5.83.